In conditions of anticoagulant/antiplatelet treatment, lower PAI1 levels would favour plasmin-dependent activation of the excess of cancer-derived TGF-β secreted by cancer cells and the cells in cancer microenvironment (Fig. 1C). Here, TGFB1 is linked to cancer.